For LDL-C reduction in patients with primary hyperlipidemia along with diet and statin therapy¹

Navigate through the real-world experiences and uncover invaluable insights and answers to crucial questions specifically curated for you to gain a deeper understanding of what truly matters most.

EXPANDED INDICATION ENABLES BROADER USE OF LEQVIO

In July 2023, the FDA approved the revised indication for use in patients with primary hyperlipidemia in addition to ESTABLISHED ASCVD and HeFH

Implementation of LEQVIO in a Real-World Setting: EXPERT INSIGHTS 

Watch Dr Michael Koren, a clinical trial investigator for the V-INITIATE trial, discuss the importance of early LEQVIO use in patients with ASCVD, immediately after failure to reach LDL-C goals with statins.

LEQVIO Clinical Insights: Understanding Pivotal Phase 3 and Long-Term Trial Data

Watch Dr Dean Karalis and Dr Merle Myerson share clinical perspectives on the LEQVIO efficacy and safety data for managing LDL-C in patients with ASCVD, including some long-term data.

How Do You Get Your Patients Started on LEQVIO?

Watch Dr Suzanne Shugg, Dr Rajkumar Sugumaran, and Dr Prediman K. Shah discuss the flexible pathways available for acquisition and administration to patients.

LEQVIO via Buy-and-Bill With In-Office Administration

Find out more about acquiring HCP-administered products like LEQVIO through buy-and-bill, the primary method of acquisition.

LEQVIO via Referral to an Alternate Injection Center (AIC)

If buy-and-bill is not your method of choice for acquiring LEQVIO, get details on how you can refer patients to an AIC or Alternate Site of Care (ASOC) to handle ordering, administration, and reimbursement for all services.